Recent executive actions have accelerated federal cannabis rescheduling. In December 2025, an executive order directed expedited rulemaking to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. April 2026 orders immediately transferred FDA-approved products and state-licensed medical marijuana to Schedule III while launching a streamlined administrative hearing on broader rescheduling. That hearing opened June 29, 2026, at DEA headquarters and concluded no later than July 15, 2026, allowing evidence and testimony on medical use, abuse potential, and dependence. Trader focus now centers on the administrative law judge’s post-hearing recommendation, any final rule issuance by the DEA or Attorney General, and potential legal challenges or procedural delays that could extend the timeline beyond late 2026.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$796,389 Vol.
September 30
14%
December 31
25%
$796,389 Vol.
September 30
14%
December 31
25%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Recent executive actions have accelerated federal cannabis rescheduling. In December 2025, an executive order directed expedited rulemaking to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. April 2026 orders immediately transferred FDA-approved products and state-licensed medical marijuana to Schedule III while launching a streamlined administrative hearing on broader rescheduling. That hearing opened June 29, 2026, at DEA headquarters and concluded no later than July 15, 2026, allowing evidence and testimony on medical use, abuse potential, and dependence. Trader focus now centers on the administrative law judge’s post-hearing recommendation, any final rule issuance by the DEA or Attorney General, and potential legal challenges or procedural delays that could extend the timeline beyond late 2026.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions